{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:25:42Z","timestamp":1789129542458,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.anai.2026.07.028","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:04:15Z","timestamp":1785996255000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is remission a meaningful outcome in asthma?"],"prefix":"10.1016","author":[{"given":"Jason A.","family":"Moraczewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-2704","authenticated-orcid":false,"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2026.07.028_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02094-2020","article-title":"Trends in worldwide asthma prevalence","volume":"56","author":"Asher","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.07.028_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"175","key":"10.1016\/j.anai.2026.07.028_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0088-2024","article-title":"Biologics in severe asthma: a state-of-the-art review","volume":"34","author":"Gyawali","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"3s","key":"10.1016\/j.anai.2026.07.028_bib0004","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaci.2025.05.033","article-title":"Consensus summary on the definition of asthma remission","volume":"156","author":"Katial","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.07.028_bib0005","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0006","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.07.028_bib0007","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2026.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaip.2025.05.019","article-title":"Disease modification in severe asthma\u2014are we there yet?","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"0","key":"10.1016\/j.anai.2026.07.028_bib0009","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/JAA.S488764","article-title":"Disease modification in asthma: are we on the right way? A multidisciplinary expert Delphi consensus (MODIASTHMA consensus)","volume":"17","author":"Miralles-L\u00f3pez","year":"2024","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-024-02812-3","article-title":"Barriers to clinical remission in severe asthma","volume":"25","author":"Farinha","year":"2024","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.anai.2026.07.028_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01619-2023","article-title":"Airway remodelling in asthma and the epithelium: on the edge of a new era","volume":"63","author":"Varricchi","year":"2024","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.anai.2026.07.028_bib0012","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.anai.2026.07.028_bib0013","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2\u2009years of treatment with Benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"issue":"12","key":"10.1016\/j.anai.2026.07.028_bib0014","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2026.07.028_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1449220","article-title":"Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience","volume":"15","author":"Stanziola","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with Type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2026.07.028_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0018","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.anai.2026.07.028_bib0019","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2026.07.028_bib0021","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (Cascade): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0022","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaci.2024.11.024","article-title":"Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma","volume":"155","author":"Stewart","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.07.028_bib0023","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.07.028_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03130-2021","article-title":"Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0026","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/all.14020","article-title":"The moderating role of allergy immunotherapy in asthma progression: results of a population-based cohort study","volume":"75","author":"Schmitt","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2026.2635778","article-title":"Efficacy and safety of allergen-specific immunotherapy for allergic asthma: a meta-analysis comparing sublingual and subcutaneous routes across allergen types and age groups","volume":"58","author":"Yin","year":"2026","journal-title":"Ann Med"},{"key":"10.1016\/j.anai.2026.07.028_bib0028","article-title":"Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study","volume":"13","author":"Fritzsching","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.anai.2026.07.028_bib0029","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cea.12881","article-title":"The current and future role of biomarkers in type 2 cytokine-mediated asthma management","volume":"47","author":"Pavord","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.anai.2026.07.028_bib0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.07.028_bib0032","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01037-2023","article-title":"The association of blood eosinophil counts and FEV(1) decline: a cohort study","volume":"63","author":"Hong","year":"2024","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/ACI.0000000000001123","article-title":"Moving towards asthma remission from mechanistic understanding to clinical practice","volume":"26","author":"Virchow","year":"2026","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.07.028_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103050","article-title":"Roads to remission: evolving treatment concepts in type 2 inflammatory diseases","volume":"80","author":"Lommatzsch","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10379","key":"10.1016\/j.anai.2026.07.028_bib0035","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.07.028_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM199501193320301","article-title":"Asthma and wheezing in the first six years of life. The group Health Medical Associates","volume":"332","author":"Martinez","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.07.028_bib0037","article-title":"GINA report for asthma [e-pub ahead of print]","author":"Venkatesan","year":"2025","journal-title":"The Lancet Respiratory Medicine"},{"issue":"3s","key":"10.1016\/j.anai.2026.07.028_bib0038","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.07.028_bib0040","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/annalsats\/aaoag019","article-title":"Real-world effectiveness of asthma biologics by age of initiation and early-childhood risk factors","volume":"23","author":"Owora","year":"2026","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.anai.2026.07.028_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71240","article-title":"Remission in children receiving biologic therapy for severe asthma","volume":"60","author":"Bruce","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.anai.2026.07.028_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106228","article-title":"Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation","volume":"100","author":"Phipatanakul","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.anai.2026.07.028_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101166","article-title":"The definition of asthma remission in children: a scoping review by the WAO Paediatric Asthma Committee","volume":"19","author":"Anastasiou","year":"2026","journal-title":"World Allergy Organ J"},{"issue":"2","key":"10.1016\/j.anai.2026.07.028_bib0044","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.pharmthera.2006.05.001","article-title":"Airway remodelling in asthma: current understanding and implications for future therapies","volume":"112","author":"Tang","year":"2006","journal-title":"Pharmacol Ther"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:21:40Z","timestamp":1789125700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S1081120626003819"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.028","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is remission a meaningful outcome in asthma?","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}